Rheumnow Podcast

Putting Steroid Tapering into Practice in SLE  Tocilizumab Beats Methotrexate in GCA  GLP-1 Receptor Agonists in PsA: Mortality and MACE Safety of CAR-T  ILD in Patients with Connective Tissue Disease  SLGT-2 and GLP-1 in RA: More than Weight Loss  PsA Predictors  Ianalumab: Breakthrough Therapy in Sjogren's

Off the Shelf: CAR-T  Combining CAR-T with CAR-Treg All in One  Tapering in SELECT GCA: Steroids are the Problem  Diagnostic Delays in PsA: A Radiographic Perspective  Late-Breaking Trials in axSpA and PsA  New Approaches to Therapy in PsA  PRED-SAFE: Chronic Prednisone Use  PsA and Brain Fog  CAR-T Therapy: Where is it Heading? 

Join RheumNow Faculty Drs. David Liew, Antoni Chan,  Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap on Monday, October 27th, at the 2025 ACR Convergence meeting in Chicago.

A Nose for Vasculitis: ENT Manifestations in ANCA-Associated Disease  Tofacitinib in AxSpA in Developing Countries  Specialized Biomarkers in PsA  B Cell Depletion: Check the Lymph Node  GLP-1 and SGLT-2: Treatments Too Good to Ignore?  Nerandomilast for ILD  PsA: Impact of Sex  Cellular Biomarkers of Rheumatoid Arthritis  Using AI and LLMs in Qualitative Data  Belimumab Before or After Immunosuppressant  Do Patients with Rheumatic Diseases 'Weather' the Storm?  AI in Fellow Recruitment: A New Dawn in Medical Education? 

AI Scribes Found their Favorite Doctors  Hospitalization in Stills: Is it "Still" an Infection? Upadacitinib is a Double Edged Vascular Sword in GCA  Rheumatoid Arthritis: Inject the Steroids Catching AxSpA Early: Closing the Diagnostic Gap  Is Low Disease Activity Low Enough?  Early Peripheral SpA: Is it okay to stop treatment sometimes? Difficult to Manage axSpA

STOP RA Cellular & Serologic Predictors Is AI Smarter than a Doctor? Lung Disease in ANCA-associated Vasculitis  Older Adults Underrepresented in RCTs  Next Generation T-Cell Engager: The Future Lupus in Focus: 2025 ACR Treatment Guidelines for SLE  Psoriatic Arthritis Imaging   

Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1.

Dr. Jack Cush reviews the news and info reports the day before ACR 2025.

DERM on RheumNow PODCAST (October 2025) Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES 1. Skin Biopsies to Predict Scleroderma Outcomes?  2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8 3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis  https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis    4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH   5. Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz 6. Mediterranean Diet Efficacy in Psoriasis   7. Gender Complexities in Psoriatic Arthritis Treatment Outcomes

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.